Patent: 10,214,585
✉ Email this page to a colleague
Summary for Patent: 10,214,585
| Title: | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| Abstract: | A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment. |
| Inventor(s): | Eisenbach-Schwartz; Michal (Rehovot, IL), Baruch; Kuti (Rehovot, IL), Rosenzweig; Neta (Rehovot, IL) |
| Assignee: | Yeda Research and Development Co., Ltd. (Rehovot, IL) |
| Application Number: | 14/850,794 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,214,585
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | ⤷ Try a Trial | 2034-03-12 |
| Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 03/08/2019 | ⤷ Try a Trial | 2034-03-12 |
| Emd Serono, Inc. | BAVENCIO | avelumab | Injection | 761049 | 03/23/2017 | ⤷ Try a Trial | 2034-03-12 |
| Astrazeneca Uk Ltd | IMFINZI | durvalumab | Injection | 761069 | 05/01/2017 | ⤷ Try a Trial | 2034-03-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
